Latigo Biotherapeutics (NASDAQ:LTGO) Releases Quarterly Earnings Results

Latigo Biotherapeutics (NASDAQ:LTGO) announced its earnings results on Thursday. The company reported ($27.59) earnings per share (EPS) for the quarter, Zacks reports.

Latigo Biotherapeutics Trading Up 3.3%

Shares of NASDAQ LTGO opened at $22.48 on Friday. Latigo Biotherapeutics has a 52-week low of $17.22 and a 52-week high of $25.93.

Insider Buying and Selling at Latigo Biotherapeutics

In other news, Director James B. Tananbaum purchased 140,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the purchase, the director directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. The trade was a 7.49% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the insider directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Leerink Partners started coverage on Latigo Biotherapeutics in a research report on Tuesday. They issued an “outperform” rating and a $36.00 price objective for the company. Guggenheim began coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 target price on the stock. The Goldman Sachs Group assumed coverage on Latigo Biotherapeutics in a research note on Tuesday. They issued a “buy” rating and a $73.00 price target on the stock. Jefferies Financial Group started coverage on Latigo Biotherapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 price target for the company. Finally, Wall Street Zen raised shares of Latigo Biotherapeutics to a “hold” rating in a research note on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Latigo Biotherapeutics presently has a consensus rating of “Buy” and an average price target of $52.25.

Key Headlines Impacting Latigo Biotherapeutics

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Latigo completed an upsized initial public offering, including full exercise of the underwriters’ option, generating $397.4 million in gross proceeds. Combined with existing cash, management expects to fund operations into 2029, reducing near-term financing and dilution concerns. Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: The New England Journal of Medicine published positive results from an abdominoplasty trial of onzotrigine, formerly known as LTG-001, in patients with moderate-to-severe acute pain. The publication adds credibility to Latigo’s lead clinical program and could support future development and partnering interest. Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: New coverage from Leerink Partners, Jefferies, Guggenheim and Goldman Sachs was bullish, with ratings ranging from “outperform” to “buy.” Price targets of $36, $50 and $73 imply substantial potential upside from recent trading levels, increasing institutional visibility for LTGO.
• Neutral Sentiment: Latigo expanded its leadership team by appointing Naomi Lowy, M.D., a former FDA deputy director in anesthesia, addiction medicine and pain medicine, as senior vice president of global regulatory affairs. Her regulatory experience may help advance the company’s clinical programs.
• Negative Sentiment: Latigo reported a quarterly loss of $27.59 per share. Although substantial losses are common for development-stage biotechnology companies, the result underscores the company’s lack of commercial revenue and ongoing dependence on its cash balance and future clinical progress.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.